AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds
AstraZeneca is increasing its prospects in cardiometabolic illness, paying $1.2 billion to start a partnership on eight applications that embrace ...
Tag: 1.2B
Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition
Eli Lilly is building its prospects in immunology through the $1.2 billion acquisition of Ventyx Biosciences, a clinical-stage company with ...
Discover the latest in health and fitness with Your Health 247. Get expert advice, workout routines, healthy recipes, and mental wellness tips to lead a healthier, happier life. Stay informed and empowered with us!